Sequent Scientific Limited — Investor Meet, 21-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

SeQuent Scientific delivered strong Q2 FY26 results with revenue up 15% YoY to 424 Cr and Adjusted EBITDA soaring 47% to 65.7 Cr (15.5% margin). PAT nearly tripled to 19.6 Cr. The NCLT approved the SeQuent-Viyash merger, creating a combined entity with Q2 revenue of 852 Cr and 22% EBITDA margin.

Management sees significant synergy potential, focusing on companion animals and R&D. Viyash's Q2 revenue grew 17.8% to 428 Cr, with EBITDA up 96% to 123 Cr (28.8% margin). The outlook is confident on sustained double-digit growth and 20%+ EBITDA margins driven by new products, operational efficiencies, and merger synergies.